Pegoretti, Valentina
Bauer, Jan
Fischer, Roman
Paro, Iskra
Douwenga, Wanda
Kontermann, Roland E.
Pfizenmaier, Klaus
Houben, Evelien
Broux, Bieke
Hellings, Niels
Baron, Wia
Laman, Jon D.
Eisel, Ulrich L. M.
Funding for this research was provided by:
Stichting MS Research (15-898 MS)
Resano
Baliopharm
Belgian Charcot Foundation
Fonds voor Wetenschappelijk Onderzoek
Article History
Received: 1 February 2023
Accepted: 20 April 2023
First Online: 3 May 2023
Declarations
:
: Animal experiments were carried out in accordance with the European Directive (2010/63/EU) on the protection of animals used for scientific purposes.
: Not applicable.
: K.P. and R.E.K. are named inventors on a patent covering the TNFR1 antagonist; K.P., R.F. and R.E.K. are named inventors on a patent covering the TNFR2 agonist. R.E.K. is a consultant for Immatics, Roche, SunRock and Oncomatryx. K.P. is a consultant for SunRock and Oncomatryx.